한글목차

펩티드계 항생제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 57억 7,000만 달러에서 2026년에는 63억 2,000만 달러에 이르고, CAGR 9.6%로 성장할 전망입니다. 지난 수년간의 성장은 항생제 내성균주 증가, 병원 내 감염률 증가, 펩타이드 합성기술의 발전, 감염질환 분야 임상연구 확대, 항생제 연구개발에 대한 정부 자금 지원 등이 요인으로 꼽힙니다.

펩티드계 항생제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 90억 4,000만 달러에 이르고, CAGR은 9.3%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 다제내성 감염증의 확산, 세계 헬스케어 인프라 확대, 펩타이드 전달 시스템의 기술 발전, CDMO와의 협력 강화, 정밀의료 접근법에 대한 인식 제고 및 채택 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 다제내성(MDR) 감염 대책 솔루션에 대한 수요 증가, 병원 내 감염에 대한 펩타이드 항생제 적용 확대, 위탁생산 및 CDMO 협력의 성장, 개별화 및 표적형 항생제 요법 도입 확대, 독성 및 부작용이 감소된 펩타이드 항생제에 대한 집중 등이 있습니다. 꼽을 수 있습니다.

다양한 감염성 질환의 확산이 펩타이드계 항생제 시장의 성장을 견인할 것으로 예측됩니다. 감염이란 세균, 곰팡이, 기생충 등 유해한 미생물에 의해 발생하는 질병을 말합니다. 감염병 증가의 주요 요인으로는 급격한 도시화, 기후 변화, 질병 발생 위험 증가 등을 들 수 있으며, 이는 펩타이드계 항생제 수요 증가로 이어지고 있습니다. 펩타이드계 항생제는 세균의 세포막을 물리적으로 파괴하여 항균 효과를 발휘합니다. 예를 들어, 2024년 5월 현재 스위스에 본부를 둔 국제기구인 세계보건기구(WHO)의 보고에 따르면, 2024년 4월까지 북미와 남미의 뎅기열 발병 건수는 이미 700만 건을 넘어섰으며, 2023년 연간 기록인 460만 건을 훌쩍 뛰어넘었습니다. 따라서 감염성 질환의 발생률 증가가 펩타이드계 항생제 시장의 성장에 기여하고 있다고 할 수 있습니다.

만성질환의 유병률 증가도 펩타이드계 항생제 시장의 성장을 가속할 것으로 예측됩니다. 만성질환이란 1년 이상 지속되고 지속적인 의료관리가 필요하며 일상생활에 제한을 초래하는 병태를 말합니다. 만성질환 증가는 흡연율 증가, 건강에 해로운 식습관, 운동 부족, 과도한 음주, 기타 생활습관 관련 요인에 기인합니다. 펩타이드계 항생제는 약물을 표적 부위에 직접 전달하여 만성질환 치료에 활용됩니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)가 발표한 예측에 따르면, 2050년까지 3,500만 명 이상의 암 환자가 새로 발생할 것으로 예상되며, 이는 2022년 추정 환자 수 2,000만 명에 비해 77% 증가한 수치입니다. 따라서 만성질환의 유병률 증가가 펩타이드계 항생제 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Peptide antibiotics are antibiotics composed of peptides, with their antibacterial action primarily driven by the physical disruption of bacterial cell membranes. These antibiotics penetrate bacterial membranes, accumulate inside the cells, and subsequently interfere with essential bacterial functions.

The primary types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics act by destroying or modifying the drug, altering the drug target, reducing or increasing drug uptake, or replacing a metabolic pathway as the drug's target. Ribosomally synthesized peptide antibiotics are antimicrobial peptides produced by ribosomes and are generated by nearly all forms of life, ranging from bacteria to plants and animals. Common peptide antibiotic drugs include daptomycin, dalbavancin, telavancin, and others, which are used to treat conditions such as skin infections, hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), bloodstream infections, and other diseases. Peptide antibiotics are utilized and distributed through hospitals, homecare settings, specialty clinics, and other distribution channels.

Tariffs have impacted the peptide antibiotics market by increasing import costs for raw materials and specialized manufacturing equipment, leading to higher production expenses. The ribosomal and non-ribosomal synthesized peptide antibiotics segments are particularly affected, especially in regions like North America and Europe that rely on global supply chains. While some local manufacturers may benefit from protection against foreign competition, overall, tariffs are creating cost pressures that encourage investments in domestic production and supply chain diversification.

The peptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide antibiotics market size has grown strongly in recent years. It will grow from $5.77 billion in 2025 to $6.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rise of antibiotic-resistant bacterial strains, increased hospital-acquired infection rates, advancements in peptide synthesis technologies, growing clinical research in infectious diseases, government funding for antibiotic R&D.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $9.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of multi-drug resistant infections, expansion of global healthcare infrastructure, technological advancements in peptide delivery systems, increasing collaborations with cdmos, rising awareness and adoption of precision medicine approaches. Major trends in the forecast period include rising demand for multi-drug resistant (mdr) infection solutions, expansion of peptide antibiotics in hospital-acquired infections, growth of contract manufacturing and cdmo collaborations, increasing adoption of personalized and targeted antibiotic therapies, focus on peptide antibiotics with reduced toxicity and side effects.

The growing prevalence of various infectious diseases is expected to drive the growth of the peptide antibiotics market. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, fungi, parasites, and others. Key factors contributing to the rise in infectious diseases include rapid urbanization, climate change, and an increased risk of disease emergence, among others, which have led to higher demand for peptide antibiotics. Peptide antibiotics exert their antibacterial effects by physically disrupting bacterial cell membranes. For example, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, dengue cases in the Americas had already exceeded seven million by April 2024, significantly higher than the 4.6 million cases recorded throughout 2023. Therefore, the rising incidence of infectious diseases is contributing to the growth of the peptide antibiotics market.

A rise in the prevalence of chronic diseases is anticipated to drive the growth of the peptide antibiotics market. Chronic diseases are conditions that persist for a year or longer, require continuous medical management, and restrict daily activities. The growing burden of chronic illnesses is attributed to factors such as increased tobacco use, unhealthy diets, lack of physical activity, excessive alcohol consumption, and other lifestyle-related causes. Peptide antibiotics are utilized in the treatment of chronic diseases by delivering the medication directly to the targeted area. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Hence, the rising prevalence of chronic diseases is contributing to the growth of the peptide antibiotics market.

Major companies operating in the peptide antibiotics market are introducing generic versions to offer more affordable treatment options for patients. Generic peptide antibiotics are lower-cost, off-patent alternatives to branded peptide-based antibiotics and are used to treat a range of bacterial infections. For example, in July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its product portfolio by launching a generic version of Daptomycin for Injection. Daptomycin for Injection is a peptide antibiotic classified as a cyclic lipopeptide and is produced through a non-ribosomal synthesis process. The generic formulation is available in 350 mg and 500 mg strengths and is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients as well as pediatric patients aged 1 to 17 years.

Major companies operating in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Basilea Pharmaceutica Ltd.

North America was the largest region in the peptide antibiotics market in 2025. The regions covered in the peptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Antibiotics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Ribosomal Synthesized Peptide Antibiotics; Non-Ribosomal Synthesized Peptide Antibiotics
• 2) By Drugs: Daptomycin; Dalbavancin; Telavancin; Other Drugs
• 3) By Disease Outlook: Skin Infection; HABP Or VABP; Blood Stream Infection; Other Diseases
• 4) By Distribution Channel: Hospitals; Homecare; Specialty Clinics; Other Distribution Channels
• Subsegments:
• 1) By Ribosomal Synthesized Peptide Antibiotics: Aminoglycosides; Macrolides; Tetracyclines; Lincosamides
• 2) By Non-Ribosomal Synthesized Peptide Antibiotics: Bacitracins; Vancomycin; Polymyxins; Cyclic Lipopeptides
• Companies Mentioned: Eli Lilly and Company; GlaxoSmithKline plc; Novartis AG; Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sandoz International GmbH; Xellia APS; Johnson & Johnson Inc.; AstraZeneca PLC; Bayer AG; Bristol-Myers Squibb Company; Lupin Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Torrent Pharmaceuticals Ltd.; Wockhardt Ltd.; Zydus Lifesciences Limited; Alkem Laboratories Limited; Allecra Therapeutics GmbH; Basilea Pharmaceutica Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Peptide Antibiotics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Peptide Antibiotics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Peptide Antibiotics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Peptide Antibiotics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rising Demand For Multi-Drug Resistant (Mdr) Infection Solutions
  • 4.2.2 Expansion Of Peptide Antibiotics In Hospital-Acquired Infections
  • 4.2.3 Growth Of Contract Manufacturing And Cdmo Collaborations
  • 4.2.4 Increasing Adoption Of Personalized And Targeted Antibiotic Therapies
  • 4.2.5 Focus On Peptide Antibiotics With Reduced Toxicity And Side Effects

5. Peptide Antibiotics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Providers
• 5.4 Pharmaceutical Companies
• 5.5 Research & Academic Institutions

6. Peptide Antibiotics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide Antibiotics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Peptide Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Peptide Antibiotics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Peptide Antibiotics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Peptide Antibiotics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide Antibiotics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide Antibiotics Market Segmentation

• 9.1. Global Peptide Antibiotics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics
• 9.2. Global Peptide Antibiotics Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Daptomycin, Dalbavancin, Telavancin, Other Drugs
• 9.3. Global Peptide Antibiotics Market, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Skin Infection, HABP Or VABP, Blood Stream Infection, Other Diseases
• 9.4. Global Peptide Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other Distribution Channels
• 9.5. Global Peptide Antibiotics Market, Sub-Segmentation Of Ribosomal Synthesized Peptide Antibiotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Aminoglycosides, Macrolides, Tetracyclines, Lincosamides
• 9.6. Global Peptide Antibiotics Market, Sub-Segmentation Of Non-Ribosomal Synthesized Peptide Antibiotics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Bacitracins, Vancomycin, Polymyxins, Cyclic Lipopeptides

10. Peptide Antibiotics Market Regional And Country Analysis

• 10.1. Global Peptide Antibiotics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Peptide Antibiotics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide Antibiotics Market

• 11.1. Asia-Pacific Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide Antibiotics Market

• 12.1. China Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide Antibiotics Market

• 13.1. India Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide Antibiotics Market

• 14.1. Japan Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide Antibiotics Market

• 15.1. Australia Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide Antibiotics Market

• 16.1. Indonesia Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide Antibiotics Market

• 17.1. South Korea Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide Antibiotics Market

• 18.1. Taiwan Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide Antibiotics Market

• 19.1. South East Asia Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide Antibiotics Market

• 20.1. Western Europe Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide Antibiotics Market

• 21.1. UK Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide Antibiotics Market

• 22.1. Germany Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide Antibiotics Market

• 23.1. France Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide Antibiotics Market

• 24.1. Italy Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide Antibiotics Market

• 25.1. Spain Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide Antibiotics Market

• 26.1. Eastern Europe Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide Antibiotics Market

• 27.1. Russia Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide Antibiotics Market

• 28.1. North America Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide Antibiotics Market

• 29.1. USA Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide Antibiotics Market

• 30.1. Canada Peptide Antibiotics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide Antibiotics Market

• 31.1. South America Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide Antibiotics Market

• 32.1. Brazil Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide Antibiotics Market

• 33.1. Middle East Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide Antibiotics Market

• 34.1. Africa Peptide Antibiotics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Peptide Antibiotics Market, Segmentation By Type, Segmentation By Drugs, Segmentation By Disease Outlook, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide Antibiotics Market Regulatory and Investment Landscape

36. Peptide Antibiotics Market Competitive Landscape And Company Profiles

• 36.1. Peptide Antibiotics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Peptide Antibiotics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Peptide Antibiotics Market Company Profiles
  • 36.3.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Peptide Antibiotics Market Other Major And Innovative Companies

• AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH

38. Global Peptide Antibiotics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide Antibiotics Market

40. Peptide Antibiotics Market High Potential Countries, Segments and Strategies

• 40.1 Peptide Antibiotics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Peptide Antibiotics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Peptide Antibiotics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer